



## Product Portfolio

Myriad Genetics: Saving lives every day



Myriad's products provide life-saving information, improve the quality of life, and help reduce healthcare costs.

## BRACAnalysis®

A predictive medicine product for hereditary breast and ovarian cancer.

BRACAnalysis® testing assesses a woman's risk of developing hereditary breast or ovarian cancer based on detection of mutations in the *BRCA1* and *BRCA2* genes. This test has become the standard of care in identification of individuals with hereditary breast and ovarian cancer.

## COLARIS®

A predictive medicine product for Lynch syndrome.

COLARIS® testing assesses a person's risk of developing hereditary colorectal cancer and a woman's risk of developing hereditary uterine cancer. COLARIS detects disease-causing mutations in the *MLH1*, *MSH2*, *MSH6*, *PMS2* and *EPCAM* genes which are responsible for the majority of Lynch syndrome.

## COLARIS AP®

A predictive medicine product for adenomatous polyposis colon cancer syndromes.

COLARIS AP® testing assesses a person's risk of developing hereditary colorectal polyps and cancer. COLARIS AP detects mutations in the *APC* and *MYH* genes, which cause adenomatous polyposis colon cancer syndromes, including familial adenomatous polyposis (FAP), attenuated FAP (AFAP), and *MYH*-associated polyposis (MAP).

## MELARIS®

A predictive medicine product for hereditary melanoma.

MELARIS® testing assesses a person's risk of developing hereditary melanoma. This test detects inherited mutations in the *p16* gene (also called *CDKN2A* or *INK4A*), which are associated with hereditary melanoma.

## PANEXIA™

A predictive medicine product for hereditary pancreatic and related cancers.

PANEXIA® testing assesses a person's risk of developing hereditary pancreatic cancer. Panexia offers insight about the risk of future hereditary cancers for patients and their families. PANEXIA analyzes the *PALB2* and *BRCA2* genes, the two genes most commonly mutated in families with hereditary pancreatic cancer.

## PREZEON™

A personalized medicine product to assess the status of the PTEN gene.

PREZEON™ testing assesses loss of *PTEN* function in cancer patients, which is associated with more aggressive disease progression and poorer survival. The *PTEN* gene is a major tumor suppressor that plays a critical role in cell signaling pathways that are the target of cancer drugs, such as EGFR and mTOR inhibitors.

## TheraGuide® 5-FU

A personalized medicine product to predict toxicity to 5-FU-based chemotherapy.

TheraGuide® 5-FU testing assesses a person's risk of developing a severe toxic reaction to 5-FU-based chemotherapy. It detects variations in 2 genes, dihydropyrimidine dehydrogenase (*DPYD*) and thymidylate synthetase (*TYMS*), that are responsible for a significant portion of serious adverse reactions to 5-FU-based therapy.

## Prolaris®

A prognostic medicine product for prostate cancer.

Prolaris™ testing assesses the prostate cancer aggressiveness in conjunction with other clinical parameters. Prolaris measures the expression level of genes involved with cell cycle progression in tumor specimens to predict disease outcome.



#### MYRIAD'S EXTENSIVE EXPERIENCE:

Myriad has over 20 years' experience in perfecting the analysis of DNA. Approximately 1 million patients have been tested and over 16,000 unique mutations have been identified by Myriad. New mutations are found and variants are classified every day. Myriad has built and maintains a proprietary database that is larger than any other, allowing Myriad to provide fast, accurate answers and to have the lowest Variant of Uncertain Significance rate in the world.

#### LARGEST MEDICAL SERVICES DEPARTMENT:

Myriad provides invaluable education and support during the entire genetic testing process as a standard part of our service. Myriad employs a full-time staff of highly trained individuals for case consultation, result interpretation and mutation classification.



MYRIAD®

Myriad Genetics GmbH  
Leutschenbachstrasse 95  
8050 Zurich  
Switzerland

[www.myriad.com](http://www.myriad.com)

Myriad, the Myriad logo, BRACAnalysis, the BRACAnalysis logo, COLARIS, the COLARIS logo, Colaris AP, the Colaris AP logo, MELARIS, the MELARIS logo, PANEXIA, the PANEXIA logo, PREZEON, the PREZEON logo, TheraGuide 5-FU, the TheraGuide 5-FU logo, Prolaris and the Prolaris logo are either trademarks or registered trademarks of Myriad Genetics, Inc., in the United States and other jurisdictions.  
©2012, Myriad Genetic Laboratories, Inc.